Nontuberculous Mycobacterial Infections Clinical Trial
Official title:
Clinical Efficacy of Rifabutin in the Treatment of Serious and Life Threatening Infections Due to Mycobacterium Avium Complex, or Drug Resistant Mycobacterium Tuberculosis, or Other Drug Resistant Mycobacterium
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections
who have failed or are intolerant of rifampin.
Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or
intolerant of rifampin.
Rifabutin dosage 150-300 mg daily( depending upon age, and clinical conditions) in NTM patients who fail treatment with rifampin. ;